Advertisement

Ocular Herpes Simplex

  • Shruti Aggarwal
  • Deborah Pavan-Langston
Chapter

Abstract

Herpes simplex virus (HSV) can present as a variety of ocular diseases. Keratitis, including epithelial and stromal, is a leading cause of infectious corneal blindness, particularly in developed countries. Most humans are infected with HSV-1 in early childhood and maintain latent infection throughout their lifetime. While majority remain asymptomatic, some can reactivate and also experience recurrences. Recent epidemiological studies show that the incidence and prevalence of ocular HSV are on the rise. This chapter reviews the clinical disease, traditional and evolving medical and surgical therapeutic options, and future directions in prevention strategies, including development of vaccination.

Keywords

Ocular herpes simplex Herpes simplex keratitis Recurrent herpes simplex keratitis Dendritic keratitis Stromal keratitis Inflammation High-risk corneal graft 

References

  1. 1.
    Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357(9267):1513–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Farooq AV, Shukla D. Herpes simplex epithelial and stromal keratitis: an epidemiologic update. Surv Ophthalmol. 2012;57(5):448–62.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Young RC, Hodge DO, Liesegang TJ, Baratz KH. Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976–2007: the effect of oral antiviral prophylaxis. Arch Ophthalmol. 2010;128(9):1178–83.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Labetoulle M, Auquier P, Conrad H, et al. Incidence of herpes simplex virus keratitis in France. Ophthalmology. 2005;112(5):888–95.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Liesegang TJ, Melton LJ 3rd, Daly PJ, Ilstrup DM. Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107(8):1155–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rowe AM, St Leger AJ, Jeon S, Dhaliwal DK, Knickelbein JE, Hendricks RL. Herpes keratitis. Prog Retin Eye Res. 2013;32:88–101.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Looker KJ, Magaret AS, May MT, et al. First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Health. 2017;5(3):e300–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chong EM, Wilhelmus KR, Matoba AY, Jones DB, Coats DK, Paysse EA. Herpes simplex virus keratitis in children. Am J Ophthalmol. 2004;138(3):474–5.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lairson DR, Begley CE, Reynolds TF, Wilhelmus KR. Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis. Arch Ophthalmol. 2003;121(1):108–12.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Toma HS, Murina AT, Areaux RG Jr, et al. Ocular HSV-1 latency, reactivation and recurrent disease. Semin Ophthalmol. 2008;23(4):249–73.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci. 2005;46(1):241–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Borkar DS, Gonzales JA, Tham VM, et al. Association between atopy and herpetic eye disease: results from the pacific ocular inflammation study. JAMA Ophthalmol. 2014;132(3):326–31.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kothari MT, Mehta BK, Asher NS, Kothari KJ. Recurrence of bilateral herpes simplex virus keratitis following bimatoprost use. Indian J Ophthalmol. 2006;54(1):47–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Green LK, Pavan-Langston D. Herpes simplex ocular inflammatory disease. Int Ophthalmol Clin. 2006;46(2):27–37.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kimberlin DW, Whitley RJ. Neonatal herpes: what have we learned? Semin Pediatr Infect Dis. 2005;16:7–16.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Silva RA, Berrocal AM, Moshfeghi DM, Blumenkranz MS, Sanislo S, Davis JL. Herpes simplex virus type 2 mediated acute retinal necrosis in a pediatric population: case series and review. Graefes Arch Clin Exp Ophthalmol. 2013;251(2):559–66.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Khan BF, Pavan-Langston D. Clinical manifestations and treatment modalities in herpes simplex virus of the ocular anterior segment. Int Ophthalmol Clin. 2004;44(3):103–33.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kalezic T, Mazen M, Kuklinski E, Asbell P. Herpetic eye disease study: lessons learned. Curr Opin Ophthalmol. 2018;29(4):340–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Dua HS, Said DG, Messmer EM, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107–31.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hamrah P, Sahin A, Dastjerdi MH, et al. Cellular changes of the corneal epithelium and stroma in herpes simplex keratitis: an in vivo confocal microscopy study. Ophthalmology. 2012;119(9):1791–7.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med. 1998;339(5):300–6.Google Scholar
  22. 22.
    Miserocchi E, Iuliano L, Fogliato G, et al. Bilateral acute retinal necrosis: clinical features and outcomes in a multicenter study. Ocul Immunol Inflamm. 2018:1–9.Google Scholar
  23. 23.
    Satpathy G, Behera HS, Sharma A, et al. A 20-year experience of ocular herpes virus detection using immunofluorescence and polymerase chain reaction. Clin Exp Optom. 2018;101(5):648–51.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tei M, Nishida K, Kinoshita S. Polymerase chain reaction detection of herpes simplex virus in tear fluid from atypical herpetic epithelial keratitis after penetrating keratoplasty. Am J Ophthalmol. 1996;122(5):732–5.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Athmanathan S, Bandlapally S, Rao GN. Comparison of the sensitivity of a 24 h-shell vial assay, and conventional tube culture, in the isolation of herpes simplex virus - 1 from corneal scrapings. BMC Clin Pathol. 2002;2(1):1.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Moein HR, Kheirkhah A, Muller RT, Cruzat AC, Pavan-Langston D, Hamrah P. Corneal nerve regeneration after herpes simplex keratitis: a longitudinal in vivo confocal microscopy study. Ocul Surf. 2018;16(2):218–25.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Muller RT, Pourmirzaie R, Pavan-Langston D, et al. In vivo confocal microscopy demonstrates bilateral loss of endothelial cells in unilateral herpes simplex keratitis. Invest Ophthalmol Vis Sci. 2015;56(8):4899–906.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Shiraki K. Antiviral drugs against alphaherpesvirus. Adv Exp Med Biol. 2018;1045:103–22.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
  30. 30.
    Klysik K, Pietraszek A, Karewicz A, Nowakowska M. Acyclovir in the treatment of herpes viruses – a review. Curr Med Chem. 2018.Google Scholar
  31. 31.
    Lee SY, Pavan-Langston D. Role of acyclovir in the treatment of herpes simplex virus keratitis. Int Ophthalmol Clin. 1994;34(3):9–18.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Roozbahani M, Hammersmith KM. Management of herpes simplex virus epithelial keratitis. Curr Opin Ophthalmol. 2018;29(4):360–4.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Liu S, Pavan-Langston D, Colby KA. Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes. Ophthalmology. 2012;119(10):2003–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Sheffield JS, Hollier LM, Hill JB, Stuart GS, Wendel GD. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol. 2003;102(6):1396–403.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Harris JB, Holmes AP. Neonatal herpes simplex viral infections and acyclovir: an update. J Pediatr Pharmacol Ther. 2017;22(2):88–93.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Tuli S, Gray M, Shah A. Surgical management of herpetic keratitis. Curr Opin Ophthalmol. 2018;29(4):347–54.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Li J, Ma H, Zhao Z, et al. Deep anterior lamellar keratoplasty using precut anterior lamellar cap for herpes simplex keratitis: a long-term follow-up study. Br J Ophthalmol. 2014;98(4):448–53.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Brown CR, Wagoner MD, Welder JD, et al. Boston keratoprosthesis type 1 for herpes simplex and herpes zoster keratopathy. Cornea. 2014;33(8):801–5.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Khan BF, Harissi-Dagher M, Pavan-Langston D, Aquavella JV, Dohlman CH. The Boston keratoprosthesis in herpetic keratitis. Arch Ophthalmol. 2007;125(6):745–9.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Kuffova L, Knickelbein JE, Yu T, et al. High-risk corneal graft rejection in the setting of previous corneal herpes simplex virus (HSV)-1 infection. Invest Ophthalmol Vis Sci. 2016;57(4):1578–87.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Epstein RJ, Seedor JA, Dreizen NG, et al. Penetrating keratoplasty for herpes simplex keratitis and keratoconus. Allograft rejection and survival. Ophthalmology. 1987;94(8):935–44.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Bhatt UK, Abdul Karim MN, Prydal JI, Maharajan SV, Fares U. Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts. Cochrane Database Syst Rev. 2016;(11):CD007824.Google Scholar
  43. 43.
    Predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. Cornea. 2001;20(2):123–8.Google Scholar
  44. 44.
    Liesegang TJ. Epidemiology of ocular herpes simplex. Natural history in Rochester, Minn, 1950 through 1982. Arch Ophthalmol. 1989;107(8):1160–5.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Bettahi I, Nesburn AB, Yoon S, et al. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest Ophthalmol Vis Sci. 2007;48(10):4643–53.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366(1):34–43.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Khan AA, Srivastava R, Chentoufi AA, et al. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells. J Virol. 2015;89(13):6619–32.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Khan AA, Srivastava R, Vahed H, et al. Human asymptomatic epitope peptide/CXCL10-based prime/pull vaccine induces herpes simplex virus-specific gamma interferon-positive CD107(+) CD8(+) T cells that infiltrate the corneas and trigeminal ganglia of humanized HLA transgenic rabbits and protect against ocular herpes challenge. J Virol. 2018;92(16).Google Scholar
  49. 49.
    Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, Pirraglia MP, Sirianni MC. Herpes simplex virus vaccine in recurrent herpetic ocular infection. Cornea. 1999;18(1):47–51.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Shruti Aggarwal
    • 1
  • Deborah Pavan-Langston
    • 2
  1. 1.Bascom Palmer Eye Institute, Department of Cornea and Refractive SurgeryMiamiUSA
  2. 2.Harvard Medical School, Massachusetts Eye and Ear Infirmary, Department of OphthalmologyBostonUSA

Personalised recommendations